About Maze Therapeutics, Inc.
https://www.mazetx.comMaze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.
CEO
Jason V. Coloma
Compensation Summary
(Year )
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:832.31K
XSU.TO
Weight:0.03%
Shares:524.15K
IWM
Weight:0.03%
Shares:524.15K
Summary
Showing Top 3 of 81
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
TRV GP IV, LLC
Shares:6.07M
Value:$249.7M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:4.57M
Value:$187.76M
ARCH VENTURE MANAGEMENT, LLC
Shares:4.12M
Value:$169.38M
Summary
Showing Top 3 of 96
About Maze Therapeutics, Inc.
https://www.mazetx.comMaze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $32.97M ▼ | $-30.09M ▲ | 0% | $-0.66 ▲ | $-29.52M ▲ |
| Q2-2025 | $0 | $35.83M ▲ | $-33.68M ▼ | 0% | $-0.77 ▼ | $-33.03M ▲ |
| Q1-2025 | $0 | $35.4M ▲ | $-32.79M ▼ | 0% | $-0.75 ▼ | $-34.72M ▼ |
| Q4-2024 | $0 ▼ | $29.73M ▲ | $-29.58M ▼ | 0% ▲ | $-0.11 ▼ | $-29.02M ▼ |
| Q3-2024 | $2.5M | $26.73M | $-24.75M | -990.08% | $-0.06 | $-23.44M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $383.94M ▲ | $422.06M ▲ | $42.62M ▲ | $379.44M ▲ |
| Q2-2025 | $264.54M ▼ | $303.52M ▼ | $41.28M ▲ | $262.24M ▼ |
| Q1-2025 | $294.37M ▲ | $332.84M ▲ | $40.77M ▼ | $292.07M ▲ |
| Q4-2024 | $196.81M ▲ | $240.54M ▲ | $43.64M ▼ | $196.9M ▲ |
| Q3-2024 | $149.61M | $192.48M | $93.11M | $99.37M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-30.09M ▲ | $-24.64M ▲ | $-66.88M ▼ | $143.76M ▲ | $52.23M ▲ | $-24.71M ▲ |
| Q2-2025 | $-33.68M ▼ | $-30.05M ▼ | $-393K ▼ | $612K ▼ | $-29.83M ▼ | $-30.45M ▼ |
| Q1-2025 | $-32.79M ▼ | $-29.52M ▼ | $-299K ▲ | $127.38M ▲ | $97.56M ▲ | $-29.82M ▼ |
| Q4-2024 | $-29.58M ▼ | $-22.45M ▲ | $-605K ▼ | $70.26M ▲ | $47.2M ▲ | $-23.06M ▲ |
| Q3-2024 | $-24.75M | $-23.2M | $-103K | $-2.15M | $-25.46M | $-23.31M |
CEO
Jason V. Coloma
Compensation Summary
(Year )
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:832.31K
XSU.TO
Weight:0.03%
Shares:524.15K
IWM
Weight:0.03%
Shares:524.15K
Summary
Showing Top 3 of 81
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
TRV GP IV, LLC
Shares:6.07M
Value:$249.7M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:4.57M
Value:$187.76M
ARCH VENTURE MANAGEMENT, LLC
Shares:4.12M
Value:$169.38M
Summary
Showing Top 3 of 96